Treatment of Upper Extremity Deep-Vein Thrombosis

Completed · Phase 4

Conditions studied: Deep-Vein Thrombosis

In brief

The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.

Key facts

Study ID

NCT00245856

Run by

University of Oklahoma

People needed

67

Starts

2002-09-01

Expected to finish

2011-12-01

Last updated by the study team

2013-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or venogram

You may not qualify if…

• Active, clinically significant bleeding
• Known hypersensitivity to heparin or low-molecular weight heparin
• Currently pregnant or less than 1 week post-partum
• Acquired bleeding diathesis
• Known inherited bleeding disorder
• Renal failure
• Extremes of weight
• Poor performance status
• Unable to return for repeat diagnostic testing or follow-up visits

Where it is running

• Department of Veterans Affairs Medical Center — Oklahoma City, Oklahoma, United States
• University of Oklahoma Health Science Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.